News Highlights


2011 FDA authorized JN's IND for conducting Conjugated Meningococcal vaccine human trials in Hanford, California


2011 Neurology scientists bags Stroke Grant Award - US Govt.


2006-2011 Meningitis vaccine for Disease outbreaks in India & sub-Saharan




Mr. Hankins & Dr.Reddy at NG Pharma conf in Amsterdam


Dr. Orten & Dr. Reddy - presentation at CNS World Summit in San Francisco




The corporation 

JNI Medical Corp - Admin Building

Do you Know? JN is the 3rd BioPharma, developed patented Meningococcal meningitis serogroups A/C/Y/W135 diphtheria toxoid conjugate vaccine (NmVac-4dt) which is now human phase. JN also developing vaccine for Genital Herpes and therapeutic Ischemic Stroke. Inc5000 Fastest Growing Company



Meningococcal VACCINE Meningococcal meningitis vaccine for children

Our Product & Products “NmVac-4dt is among the most complex biotech or biologic products. It’s a combination vaccine that contains four 4 different vaccines in one and can be used with any combination by the geographic prevalence of the disease causing serogroup.”



Flag of the United States.svg    American Exports


To Saharan Africa, Middle East, Latin America and Asia through our subsidiaries and distributions. Export product:




Neurological THERAPIES


Research JN neurology team has developed Biomarkers and Therapeutics to intervene TIA / Stroke, Epilepsy, Alzheimer's.

  1. Vaccine saves mice

  2. Auto Antibodies NEWS

  3. Biomarkers

  4. Stroke therapeutic



Filled Commitment







US President Malaria Initiative & JN International Medical Corporation